Sterile Solutions, Built Differently.

ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the formulation, analytical and process development, sterile manufacturing (fill&finish), and testing of tomorrow’s medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients.

We're ready for what comes next.

Let's connect

As a CDMO for the pharma industry, ten23 health combines the latest scientific findings with our proven and tested world-class industry and regulatory expertise to forge new paths for our clients’ needs. From our locations in Basel and Visp, Switzerland, we provide our innovative services to pharmaceutical companies around the world in a fair and sustainable manner, respecting people’s health and the future of our planet.

Development
Strategy

Formulation
Design

Administration,
Compatibility & Usability

Drug/Device
Integration

Molecule Selection &
Characterization

Analytical Development &
Testing

Packaging &
Device Characterization

Molecules
Supported

Troubleshooting &
Regulatory Support

Manufacturing Process Transfer,
Characterization and Validation

Clinical Fill & Finish
and Commercial Supplies

Stability &
Pre-clinical Supplies

Our sites: Built for better.

We’re always preparing for what lies ahead, investing in the People, platforms and partnerships that help us stay agile and future-ready.

From expanding manufacturing capabilities to enhancing drug integration and broadening our global reach, we're laying the foundation for the next generation of therapeutic impact.

From Basel and Visp in Switzerland, we deliver our services to companies around the world with agility, speed and impact at our core.

Explore our facilities

CDMO solutions: Developed with purpose.

We lead with science to deliver CDMO solutions that disrupt.

Streamline your strategy

Master your manufacturing

Evaluate your products

Patients, People,
Planet

Delivered to Patients, driven by People.

We have a clear mission: to serve as a Patient-focused, human-centric and sustainable partner to advance stable, effective and safe injectable medicines to Patients, without compromise.

We take pride in being the first CDMO in the pharmaceutical industry for injectables/sterile drug products to have been certified as a B Corp.

Discover our purpose

We attract passionate, purpose-driven talent who share our commitment to driving real change.

Meet our team

Interested to learn more about ten23 health?

Press releases

ten23 health® strengthens leadership team to drive its next stage of growth

Basel, May 26, 2026 - ten23 announces changes to its leadership team as part of its ongoing commitment to position the company for further long-term growth. These updates reflect a thoughtful alignment of leadership to support the continued expansion of ten23’s capabilities and manufacturing capacity.

Download Press Release

ten23 health® and West collaborate to ensure manufacturing readiness for West Synchrony™ S1 Prefillable Syringe System filling

Basel, May 4, 2026 - ten23 health today announced that it has already successfully tested and ran the newly launched West Synchrony™ S1 prefillable syringe (PFS) system on its manufacturing equipment.

Download Press Release

ten23 health® expands its commercial activities into the APAC area opening office in Japan

Basel, April 15, 2026 - ten23 health announces the expansion of its commercial activities in the APAC area with the opening of a new office in Tokyo, Japan and the appointment of Noriko Utsumi as Business Development Director for Japan and the broader Asia-Pacific region.

Download Press Release

ten23 health® and BD partner to enable supply chain readiness of BD Libertas™ wearable injector as full-service solution

Basel, January 20, 2026 - ten23 health today announced a manufacturing collaboration to support the commercialization of the BD Libertas™ wearable injector. The collaboration will offer biopharma companies supply chain readiness of a fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs, helping speed development and reduce risk in complex injectable programs.

Download Press Release

ten23 health® QC lab to support commercial product testing for U.S. customer following FDA approvals

Basel, December 9, 2025 - ten23 health today announced that its recently established and Swissmedic approved Quality Control (QC) laboratories in both Basel and Visp, Switzerland, have been formally approved by the U.S. Food and Drug Administration (FDA).

Download Press Release

ten23 health^® and Neumirna Therapeutics team up to develop RNA therapy for epilepsy

Basel, October 27, 2025 - The partnership aims to accelerate clinical translation of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.

Download Press Release

BD, ten23 health, and partners to demo full RFID syringe traceability at CPHI Frankfurt

Basel, October 15, 2025 - New collaboration brings hands-on tour of unit-level traceability in injectable drug manufacturing to CPHI 2025

Download Press Release

ten23 health joins the “Alliance for RTU” - an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing

Basel, June 30, 2025 – ten23 health has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing.

Download Press Release

ten23 health establishes Advisory Board in collaboration with St. Gallen Symposium’s Young Leaders on Board

Basel, May 27, 2025 – ten23 health is proud to announce the establishment of its Advisory Board, bringing together leading global experts to confirm its commitment to a "Patients," "People," and "Planet" focused corporate social responsibility policy.

Download Press Release

ten23 health kickstarts new era with launch of industry-first robot-assisted pilot non-GMP sterile filling in its Basel facilities

Basel, May 12, 2025: Customers can now accelerate new product development with early access to non-GMP but clinically representative liquid and lyophilized batches. The pilot line is easy to access, reduces costs, and allows the use of material that would not be suitable for GMP processing.

Download Press Release

ten23 health proudly launches its GMP certified Quality Control (QC) & Testing services at its state-of-the-art Basel (BASE®) and Visp (VIVA2®) laboratories in Switzerland, celebrated with a grand opening in Basel featuring local dignitaries.

Basel, April 28, 2025 - ten23 health announces the launch of its quality control (QC) & testing services at both its Basel (BASE®) and Visp (VIVA2®) facilities

Download Press Release

ten23 health’s Fairstainability Impact Report 2024 confirms its position as a world leader in sustainable pharma manufacturing

Basel, 2 of April 2025: ten23 health is proud to announce a range of achievements and sustainability certifications, with the publication of its yearly Fairstainabilty Report.

Download Press Release

Swiss quality guaranteed

Technical knowledge, expertise, and skills; proactive communication, excellent presentations and explanations/clarifications, prompt completion of tasks, always within scheduled timelines, willingness to adjust and adapt work efforts as needed and in a timely manner.

CEO, Biotech

We really appreciate the collaborative atmosphere of working with ten23. While the ten23 technical team is highly knowledgeable, logical in their thinking, and decisive in their decision making, we have found the ten23 team to be very accommodating in their willingness/openness to discuss alternatives and work together to identify the best solution that is mutually acceptable to both parties. This is invaluable to us and we believe your team excels at this.
(This is not always the case with even some of the "best" contract manufacturers. I am sure this is true for many customers as well).

Project Lead, Top-Ten Pharma

The ten23 team did an excellent job of running the study to a very high quality and delivering fully qualified data to us on time. I was really impressed with how seamlessly this was managed without any hiccups. I am happy to work with such a great team that knows how to meet expectations and deliver high quality performance.
A big bow!

Project Lead, Top-Ten Pharma

Upcoming events

APV Workshop: Drug Device Combination Products for Parenteral Use

Basel, Switzerland

June 08, 2026

Website ⟶

CPHI Americas

Philadelphia, USA

June 02, 2026

Website ⟶

Social Media Wall